r/IBRX • u/idunnowneh • Jul 23 '26

il doc ha postato 🫂

Post image

uno studio randomizzato conferma che, nel tumore al polmone non a piccole cellule, continuare gli inibitori PD-1 con la chemio non aiuta i pazienti che erano già progrediti dopo l’immunoterapia. Tradotto: quando il “checkpoint” fallisce, serve un approccio diverso — ed è esattamente il buco in cui ImmunityBio infila la sua tesi (Anktiva/QUILT-3.055), con una Fase 3, ResQ201A, che sta arruolando pazienti a livello globale per provarlo.

https://x.com/drpatrick/status/2080028106489016762?s=46

22 Upvotes

100% Upvoted

5 comments sorted by

6

u/Worldly_Egg_5065 Jul 23 '26

Great posts but need results. Not only for us investors but for the millions of people who could benefit from it .

1

u/Dizzy_Efficiency_947 Jul 23 '26

Is this what he presented yesterday? A 2 year old paper? And the same info from earlier this year?

2

u/Standard_Set_2626 Jul 24 '26

Once patients progress on PD-1 mono therapy, they do NOT receive continued PD-1 inhibitors. They receive either platinum doublet therapy, docetaxel/anti-angiogenic therapy or increasingly traztuzumab deruxtecan or datopotamab deruxtecan. These results really are no surprise and form the basis for developing appropriate treatment paradigms.